The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Xeljanz (tofacitnib) Drug-Global Market Insights and Sales Trends 2024
Synopsis
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
The global Xeljanz (tofacitnib) Drug market size is expected to reach US$ 1119.5 million by 2029, growing at a CAGR of -5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Xeljanz (tofacitnib) Drug in various end use industries. The expanding demands from the Rheumatoid Arthritis, Psoriatic Arthritis and Other, are propelling Xeljanz (tofacitnib) Drug market. Tablets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Extended-release Tablets segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Xeljanz (tofacitnib) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Xeljanz (tofacitnib) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Xeljanz (tofacitnib) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Xeljanz (tofacitnib) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Xeljanz (tofacitnib) Drug covered in this report include Pfizer. etc.
The global Xeljanz (tofacitnib) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Global Xeljanz (tofacitnib) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Xeljanz (tofacitnib) Drug market, Segment by Type:
Tablets
Extended-release Tablets
Global Xeljanz (tofacitnib) Drug market, by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Xeljanz (tofacitnib) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Xeljanz (tofacitnib) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis
The global Xeljanz (tofacitnib) Drug market size is expected to reach US$ 1119.5 million by 2029, growing at a CAGR of -5.7% from 2023 to 2029. The market is mainly driven by the significant applications of Xeljanz (tofacitnib) Drug in various end use industries. The expanding demands from the Rheumatoid Arthritis, Psoriatic Arthritis and Other, are propelling Xeljanz (tofacitnib) Drug market. Tablets, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Extended-release Tablets segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Xeljanz (tofacitnib) Drug, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Xeljanz (tofacitnib) Drug market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Xeljanz (tofacitnib) Drug market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Xeljanz (tofacitnib) Drug sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Xeljanz (tofacitnib) Drug covered in this report include Pfizer. etc.
The global Xeljanz (tofacitnib) Drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
Global Xeljanz (tofacitnib) Drug market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Xeljanz (tofacitnib) Drug market, Segment by Type:
Tablets
Extended-release Tablets
Global Xeljanz (tofacitnib) Drug market, by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Xeljanz (tofacitnib) Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Xeljanz (tofacitnib) Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Xeljanz (tofacitnib) Drug Market Overview
1.1 Xeljanz (tofacitnib) Drug Product Overview
1.2 Xeljanz (tofacitnib) Drug Market Segment by Type
1.2.1 Tablets
1.2.2 Extended-release Tablets
1.3 Global Xeljanz (tofacitnib) Drug Market Size by Type
1.3.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Type (2018-2029)
1.3.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Type (2018-2023)
1.3.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2023)
1.4.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Type (2018-2023)
2 Global Xeljanz (tofacitnib) Drug Market Competition by Company
2.1 Global Top Players by Xeljanz (tofacitnib) Drug Sales (2018-2023)
2.2 Global Top Players by Xeljanz (tofacitnib) Drug Revenue (2018-2023)
2.3 Global Top Players by Xeljanz (tofacitnib) Drug Price (2018-2023)
2.4 Global Top Manufacturers Xeljanz (tofacitnib) Drug Manufacturing Base Distribution, Sales Area, Product Type
2.5 Xeljanz (tofacitnib) Drug Market Competitive Situation and Trends
2.5.1 Xeljanz (tofacitnib) Drug Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Xeljanz (tofacitnib) Drug Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Xeljanz (tofacitnib) Drug as of 2022)
2.7 Date of Key Manufacturers Enter into Xeljanz (tofacitnib) Drug Market
2.8 Key Manufacturers Xeljanz (tofacitnib) Drug Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Xeljanz (tofacitnib) Drug Status and Outlook by Region
3.1 Global Xeljanz (tofacitnib) Drug Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Xeljanz (tofacitnib) Drug Historic Market Size by Region
3.2.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2018-2023)
3.2.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2018-2023)
3.2.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Region
3.3.1 Global Xeljanz (tofacitnib) Drug Sales in Volume by Region (2024-2029)
3.3.2 Global Xeljanz (tofacitnib) Drug Sales in Value by Region (2024-2029)
3.3.3 Global Xeljanz (tofacitnib) Drug Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Xeljanz (tofacitnib) Drug by Application
4.1 Xeljanz (tofacitnib) Drug Market Segment by Application
4.1.1 Rheumatoid Arthritis
4.1.2 Psoriatic Arthritis
4.1.3 Other
4.2 Global Xeljanz (tofacitnib) Drug Market Size by Application
4.2.1 Global Xeljanz (tofacitnib) Drug Market Size Overview by Application (2018-2029)
4.2.2 Global Xeljanz (tofacitnib) Drug Historic Market Size Review by Application (2018-2023)
4.2.3 Global Xeljanz (tofacitnib) Drug Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2023)
4.3.2 Europe Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Xeljanz (tofacitnib) Drug Sales Breakdown by Application (2018-2023)
5 North America Xeljanz (tofacitnib) Drug by Country
5.1 North America Xeljanz (tofacitnib) Drug Historic Market Size by Country
5.1.1 North America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2023)
5.1.3 North America Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2023)
5.2 North America Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
5.2.1 North America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
5.2.2 North America Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
6 Europe Xeljanz (tofacitnib) Drug by Country
6.1 Europe Xeljanz (tofacitnib) Drug Historic Market Size by Country
6.1.1 Europe Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2023)
6.1.3 Europe Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2023)
6.2 Europe Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
6.2.1 Europe Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
6.2.2 Europe Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
7 Asia-Pacific Xeljanz (tofacitnib) Drug by Region
7.1 Asia-Pacific Xeljanz (tofacitnib) Drug Historic Market Size by Region
7.1.1 Asia-Pacific Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Xeljanz (tofacitnib) Drug Forecasted Market Size by Region
7.2.1 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Xeljanz (tofacitnib) Drug Sales in Value by Region (2024-2029)
8 Latin America Xeljanz (tofacitnib) Drug by Country
8.1 Latin America Xeljanz (tofacitnib) Drug Historic Market Size by Country
8.1.1 Latin America Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2023)
8.1.3 Latin America Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2023)
8.2 Latin America Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
8.2.1 Latin America Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
8.2.2 Latin America Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
9 Middle East and Africa Xeljanz (tofacitnib) Drug by Country
9.1 Middle East and Africa Xeljanz (tofacitnib) Drug Historic Market Size by Country
9.1.1 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Xeljanz (tofacitnib) Drug Forecasted Market Size by Country
9.2.1 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Xeljanz (tofacitnib) Drug Products Offered
10.1.5 Pfizer Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Xeljanz (tofacitnib) Drug Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Xeljanz (tofacitnib) Drug Industrial Chain Analysis
11.4 Xeljanz (tofacitnib) Drug Market Dynamics
11.4.1 Xeljanz (tofacitnib) Drug Industry Trends
11.4.2 Xeljanz (tofacitnib) Drug Market Drivers
11.4.3 Xeljanz (tofacitnib) Drug Market Challenges
11.4.4 Xeljanz (tofacitnib) Drug Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Xeljanz (tofacitnib) Drug Distributors
12.3 Xeljanz (tofacitnib) Drug Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
